Home
Knowledge Hub: e-learning materials
General Annual Meeting (GAM)
Satellite 2 – Beigene: Next generation BTK inhibitors: what’s in it for our Waldenström patients?
Satellite 2 – Beigene: Next generation BTK inhibitors: what’s in it for our Waldenström patients?
Chair: Ann Janssens
-Genomic landscape of Waldenström’s macroglobulinemia and impact on treatment?
Zachary Hunter, Dana Farber Cancer Institute, Boston, USA
-Pharmacokinetics of current BTKI and value for the clinic.
Jens Neefs, UZ Leuven, Belgium
-New Belgian guidelines
Vanessa Van Hende, VITAZ, Belgium
In short
Information sheet
Presenter
Presenters: Ann Janssens, Zachary Hunter, Jens Neefs, Vanessa Van Hende
Member login required
This content is part of our learning materials for our members. Login or see our membership information